Research programme: immunocytokines - Bright Peak Therapeutics/Ajinomoto
Latest Information Update: 30 Apr 2021
At a glance
- Originator Bright Peak Therapeutics
- Class Antineoplastics; Cytokines; Immunoproteins; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer